Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Adma Biologics, Inc. (ADMA) AI Forecast

Our AI analyzed Adma Biologics, Inc.. Create a free account to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$ADMA Neutral Signal Full forecast available
Sign Up Free

Adma Biologics, Inc. (ADMA) Stock Forecast 2025

Adma Biologics, Inc. (ADMA) AI Stock Price Forecast & Investment Analysis

Adma Biologics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Adma Biologics, Inc. (ADMA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Adma Biologics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on June 17, 2026, 4:08 p.m. (UTC)

Adma Biologics, Inc. Investment Summary

When evaluating whether Adma Biologics, Inc. (ADMA) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Adma Biologics, Inc. (ADMA) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Adma Biologics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Adma Biologics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Adma Biologics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Adma Biologics, Inc.

Sign Up Free
Corporate Identity

Adma Biologics, Inc. (Stock Symbol: ADMA) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Adma Biologics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Adma Biologics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Adma Biologics, Inc....

Unlock Full Company Profile

Get complete details about Adma Biologics, Inc.

Sign Up Free
Revenue & Growth Analysis

Adma Biologics, Inc. generates annual revenues of $509 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Adma Biologics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Adma Biologics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Adma Biologics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Adma Biologics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Adma Biologics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Adma Biologics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Adma Biologics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company shows positive operational efficiency through free cash flow generation of $108 million annually . Positive free cash flow indicates the business generates more cash than required for operations and capital investments, providing resources for growth initiatives or shareholder returns.

Asset Utilization Efficiency

Asset turnover ratio of 0.77x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 6.95 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Adma Biologics, Inc. (ADMA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Adma Biologics, Inc. stock analysis.

Deep dive into Adma Biologics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Adma Biologics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Adma Biologics, Inc.: With a P/E ratio of 12.05, the market sees the stock as potentially undervalued.

P/E Ratio 12.05x
P/B Ratio 5.11x
Market Cap $1.99B
Book Value/Share $1.68
Revenue/Share $2.19
FCF/Share $0.46
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Adma Biologics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Adma Biologics, Inc.: An ROE of -0.2% indicates room for improvement in shareholder value creation.

ROE -0.2%
ROA -0.1%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Adma Biologics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Adma Biologics, Inc.: A current ratio of 6.95 indicates strong liquidity.

Current Ratio 6.95x
Quick Ratio 3.93x
D/E Ratio 0.70x
Financial Leverage 1.70x
Interest Coverage 44.0x
Working Capital $438M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Adma Biologics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Adma Biologics, Inc.: Free cash flow of $108M provides flexibility for shareholder returns and growth investments.

Operating Cash Flow -$20K
Free Cash Flow $108M
Capital Spending $108M
FCF/Sales 21.2%
CapEx/Sales 21.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Adma Biologics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Adma Biologics, Inc.: An asset turnover of 0.77x suggests room for improvement in asset utilization.

Asset Turnover 0.77x
Receivables Turnover 3.8x
Fixed Assets Turnover 7.8x
Days Sales Outstanding 97 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Adma Biologics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Adma Biologics, Inc.: With annual revenue of $509M, Adma Biologics, Inc. demonstrates solid business size.

Income Statement
Total Revenue $509M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 511%
Cash & Short-term Investments 138%
Total Liabilities 275%
Short-term Debt 53%
Accounts Receivable 136%
Inventory 222%
Dividend & Shareholder Information
Shares Outstanding 232M

Latest Adma Biologics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Adma Biologics, Inc. (ADMA) stock price and investment outlook.

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More

Adma Biologics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Adma Biologics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $165M x 1.9x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $1M x x
Arcellx, Inc. ACLX ██% $6.73B x 16.7x
Alpha Cognition Inc. ACOG ██% $133M x 2.3x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $1.99B 12.1x 5.1x
Adaptive Biotechnologies Corp ADPT ██% $2.75B x 12.7x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $115M 1.8x x
Agentix Corp. AGTX ██% $680K x x
Aim Immunotech Inc. AIM ██% $11M x 5.2x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $171M x 16.5x
Aligos Therapeutics, Inc. ALGS ██% $31M x 1.0x
Allogene Therapeutics, Inc. ALLO ██% $656M x 2.4x
Alvotech ALVO ██% $1.21B x x
Amgen Inc AMGN ██% $187.73B 24.1x 20.4x
Apogee Therapeutics, Inc. APGE ██% $6.38B x x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $54.36B x x
Armata Pharmaceuticals, Inc. ARMP ██% $248M x x
Artiva Biotherapeutics, Inc. ARTV ██% $433M x 4.9x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $82M x x
Atyr Pharma Inc ATYR ██% $44M x 0.8x
Aura Biosciences, Inc. AURA ██% $649M x 6.1x
Autolus Therapeutics Plc AUTL ██% $397M x 3.6x
Anavex Life Sciences Corp. AVXL ██% $234M x 1.8x
Bioatla, Inc. BCAB ██% $6M x x
Biocardia, Inc. BCDA ██% $13M x x
Brainstorm Cell Therapeutics Inc. BCLI ██% $9M x x
Biocryst Pharmaceuticals Inc BCRX ██% $2.27B x x
Black Diamond Therapeutics, Inc. BDTX ██% $96M x 0.9x
Beam Therapeutics Inc. BEAM ██% $3.18B x 2.7x
Biogen Inc. BIIB ██% $28.79B 21.0x 1.5x
Biontech Se BNTX ██% $22.63B x x
Cabaletta Bio, Inc. CABA ██% $457M x 4.4x
Candel Therapeutics, Inc. CADL ██% $584M x 4.2x
C4 Therapeutics, Inc. CCCC ██% $400M x 1.7x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $8M x 1.4x
Cero Therapeutics Holdings, Inc. CERO ██% $540K x x
Cullinan Therapeutics, Inc. CGEM ██% $833M x 2.3x
Compugen Ltd CGEN ██% $192M 2.7x 1.9x
Cg Oncology, Inc. CGON ██% $5.31B x 4.9x
Cognition Therapeutics Inc CGTX ██% $113M x 3.8x
Coherus Oncology, Inc. CHRS ██% $213M 1.1x 2.7x
Calidi Biotherapeutics, Inc. CLDI ██% $3M x 0.6x
Cellectis S.A. CLLS ██% $307M x x
Compass Therapeutics, Inc. CMPX ██% $355M x 1.9x
Mosaic Immunoengineering Inc. CPMV ██% $5M x x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $86M x 2.5x
Cardiol Therapeutics Inc. CRDL ██% $122M x x
Curis Inc CRIS ██% $15M x 1.2x
Crispr Therapeutics Ag CRSP ██% $5.01B x 2.8x
Champions Oncology, Inc. CSBR ██% $96M x 22.3x
Cel Sci Corp CVM ██% $18M x 2.6x
Dbv Technologies S.A. DBVT ██% $991M x 5.9x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $506M x 1.1x
Denali Therapeutics Inc. DNLI ██% $3.48B x 3.8x
Precision Biosciences Inc DTIL ██% $163M x 2.1x
Dyadic International Inc DYAI ██% $28M x x
Editas Medicine, Inc. EDIT ██% $362M x 82.2x
Eloxx Pharmaceuticals, Inc. ELOX ██% $8M x x
Elutia Inc. ELUT ██% $41M 0.8x 1.8x
Engene Therapeutics Inc. ENGN ██% $117M x 0.5x
Entera Bio Ltd. ENTX ██% $55M x 5.2x
Viskase Holdings, Inc. ENZN ██% $37M x 0.2x
Estrella Immunopharma, Inc. ESLA ██% $42M x x
Evaxion A/S EVAX ██% $29M x x
Exelixis, Inc. EXEL ██% $13.22B 15.9x 6.8x
Exozymes Inc. EXOZ ██% $63M x 41.2x
Fate Therapeutics Inc FATE ██% $221M x 1.2x
4d Molecular Therapeutics, Inc. FDMT ██% $453M x 1.0x
Fennec Pharmaceuticals Inc. FENC ██% $309M x 8.2x
Finch Therapeutics Group, Inc. FNCH ██% $12M 0.5x 0.9x
Finch Therapeutics Group, Inc. FNCHQ ██% $12M 0.5x 0.8x
Futuretech Ii Acquisition Corp. FTII ██% $52M x x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $158.02B 17.2x 6.7x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.50B x 2.9x
Genenta Science S.P.A. GNTA ██% $44M x 3.5x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $260K x x
Greenland Mines Ltd GRML ██% $39M x 0.8x
Halozyme Therapeutics, Inc. HALO ██% $8.25B 23.7x 37.6x
Humacyte, Inc. HUMA ██% $278M x 23.9x
Immunitybio, Inc. IBRX ██% $7.04B x x
Inhibikase Therapeutics, Inc. IKT ██% $220M x 1.3x
Imagenebio, Inc. IMA ██% $61M x 0.5x
Immunocore Holdings Plc IMCR ██% $1.43B x 3.6x
Immatics N.V. IMTX ██% $1.22B x x
Immunovant, Inc. IMVT ██% $6.85B x 8.0x
In8bio, Inc. INAB ██% $14M x 0.6x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $57M x x
Inmune Bio, Inc. INMB ██% $34M x 1.7x
Intensity Therapeutics, Inc. INTS ██% $9M x 0.9x
Iovance Biotherapeutics, Inc. IOVA ██% $1.67B x 2.3x
Century Therapeutics, Inc. IPSC ██% $393M x 1.5x
Invivyd, Inc. IVVD ██% $252M x 1.2x
Jasper Therapeutics, Inc. JSPR ██% $13M x 3.7x
Kalaris Therapeutics, Inc. KLRS ██% $100M x 1.5x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.05B x 18.3x
Krystal Biotech, Inc. KRYS ██% $9.52B 42.3x 7.5x
Kymera Therapeutics, Inc. KYMR ██% $7.19B x 4.7x
Kyverna Therapeutics, Inc. KYTX ██% $479M x 2.5x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $299M x 5.6x
Lenz Therapeutics, Inc. LENZ ██% $204M x 0.8x
Atyr Pharma Inc LIFE ██% $1.57B x 27.1x
Liminatus Pharma, Inc. LIMN ██% $5M x x
Leonabio, Inc. LONA ██% $74M x 1.5x
Lexeo Therapeutics, Inc. LXEO ██% $352M x 1.5x
Maze Therapeutics, Inc. MAZE ██% $1.32B x 3.9x
Mesoblast Ltd MESO ██% $1.78B x x
Meiragtx Holdings Plc MGTX ██% $899M x x
Metagenomi Therapeutics, Inc. MGX ██% $43M x 0.3x
Molecular Partners Ag MOLN ██% $158M x x
Moderna, Inc. MRNA ██% $21.99B x 3.0x
Neurocrine Biosciences Inc NBIX ██% $15.74B 23.5x 4.6x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $281M x 4.0x
Novavax Inc NVAX ██% $1.51B x x
Ocugen, Inc. OCGN ██% $399M x 68.8x
Outlook Therapeutics, Inc. OTLK ██% $190M x x
Palisade Bio, Inc. PALI ██% $298M x 2.3x
Passage Bio, Inc. PASG ██% $18M x 1.5x
Vaxcyte, Inc. PCVX ██% $7.12B x 2.4x
Biomx Inc. PHGE ██% $6M x x
Pluri Inc. PLUR ██% $23M x x
Protalix Biotherapeutics, Inc. PLX ██% $164M 10.7x 2.5x
Pharmacyte Biotech, Inc. PMCB ██% $9M x 0.2x
Prime Medicine, Inc. PRME ██% $518M x 6.8x
Prokidney Corp. PROK ██% $510M x x
Pelthos Therapeutics Inc. PTHS ██% $94M x 2.7x
Qiagen N.V. QGEN ██% $8.07B x 2.1x
Quince Therapeutics, Inc. QNCX ██% $18M 2.1x 1.1x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $699M x 3.3x
Repligen Corp RGEN ██% $7.43B 144.5x 3.5x
Regenxbio Inc. RGNX ██% $358M x 17.0x
Relay Therapeutics, Inc. RLAY ██% $3.28B x 5.1x
Revolution Medicines, Inc. RVMD ██% $31.34B x 20.9x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.69B x 1.7x
Sab Biotherapeutics, Inc. SABS ██% $280M x 1.2x
Sana Biotechnology, Inc. SANA ██% $764M x 6.4x
Scilex Holding Co SCLX ██% $41M x x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M x 0.2x
Sangamo Therapeutics, Inc SGMO ██% $66M x x
Solid Biosciences Inc. SLDB ██% $696M x 1.9x
Silexion Therapeutics Corp SLXN ██% $3M x 9.9x
Senti Biosciences Holdings, Inc. SNTI ██% $29M x 11.3x
Scholar Rock Holding Corp SRRK ██% $5.43B x 19.7x
Surrozen, Inc./De SRZN ██% $261M x x
Sutro Biopharma, Inc. STRO ██% $467M x x
Protara Therapeutics, Inc. TARA ██% $210M x 1.2x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.64B x 7.6x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $59M x 0.6x
Bio-Techne Corp TECH ██% $8.76B 80.0x 4.2x
Tectonic Therapeutic, Inc. TECX ██% $565M x 2.5x
Instil Bio, Inc. TIL ██% $52M x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $157M x 1.5x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.72B x 8.1x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $40M x x
Twist Bioscience Corp TWST ██% $5.42B x 11.9x
Voyager Acquisition Corp./Cayman Islands VACH ██% $541M 80.4x x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $517M x x
Vericel Corp VCEL ██% $1.99B 92.8x 5.6x
Vir Biotechnology, Inc. VIR ██% $1.44B x 1.8x
Vivosim Labs, Inc. VIVS ██% $3M x 0.7x
Vor Biopharma Inc. VOR ██% $807M x x
Vaxart, Inc. VXRT ██% $138M 3.7x 1.5x
Voyager Therapeutics, Inc. VYGR ██% $220M x 1.3x
Windtree Therapeutics Inc /De/ WINT ██% $670K x x
X4 Pharmaceuticals, Inc XFOR ██% $386M x 2.3x
Zeo Scientifix, Inc. ZEOX ██% $13M x 18.6x
Zivo Bioscience, Inc. ZIVO ██% $14M x x
Zura Bio Ltd ZURA ██% $360M x 1.7x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Adma Biologics, Inc. Stock Forecast

How accurate are Adma Biologics, Inc. stock predictions?

Our AI model shows a 17% Spearman correlation coefficient for ADMA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Adma Biologics, Inc. stock price forecasts?

Our analysis considers Adma Biologics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Adma Biologics, Inc. a good investment in 2025?

Based on our AI analysis, Adma Biologics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Adma Biologics, Inc. forecasts updated?

Adma Biologics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Adma Biologics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...